- Home
- CLNN
CLNN
Clene Inc.
as 07-26-2024 4:00pm EST
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SALT LAKE CITY |
| Market Cap: | 43.8M | IPO Year: | N/A |
| Target Price: | $130.00 | AVG Volume (30 days): | 53.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -9.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.23 - $15.80 | Next Earning Date: | 08-12-2024 |
| Revenue: | $620,000 | Revenue Growth: | 12.73% |
| Revenue Growth (this year): | -47.52% | Revenue Growth (next year): | -10.85% |
Latest Clene Inc. News
CLNN Breaking Stock News: Dive into CLNN Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
GlobeNewswire
14 days ago
Clene to Present at the Emerging Growth Conference
GlobeNewswire
15 days ago
Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS
GlobeNewswire
17 days ago
Clene Announces 1-for-20 Reverse Stock Split
GlobeNewswire
a month ago
Clene to Present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference
GlobeNewswire
a month ago
Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome
GlobeNewswire
a month ago
Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting
GlobeNewswire
a month ago
Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now
Compare CLNN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLNN Clene Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.